Monitoring toxicity in individuals receiving treatment for latent tuberculosis infection: A systematic review versus expert opinion

European Respiratory Journal

Volumn 45, Issue 4, 2015, Pages 1170-1173

  Sotgiu, Giovanni ^a   Matteelli, Alberto ^b   Getahun, Haileyesus ^b   Girardi, Enrico ^c   Schepisi, Monica Sañé ^c   Centis, Rosella ^b   Migliori, Giovanni Battista ^b  

^a UNIVERSITY OF SASSARI   (Italy)

^b WORLD HEALTH ORGANIZATION   (Switzerland)

^c NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; ISONIAZID; LIVER ENZYME; RIFAMPICIN; RIFAPENTINE; TUBERCULOSTATIC AGENT;

AGE DISTRIBUTION; ALLERGIC REACTION; CAUSE OF DEATH; CYTOKINE RELEASE; DRUG SAFETY; DRUG TOLERABILITY; GASTROINTESTINAL SYMPTOM; HEALTH PROGRAM; HEPATITIS; HOSPITALIZATION; HUMAN; IMMUNE RESPONSE; LABORATORY TEST; LATENT TUBERCULOSIS; LETTER; LIVER TOXICITY; META ANALYSIS (TOPIC); MORBIDITY; MORTALITY; PATIENT MONITORING; PERIPHERAL NEUROPATHY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PUBLIC HEALTH; RISK FACTOR; SIDE EFFECT; SKIN MANIFESTATION; SYSTEMATIC REVIEW; TREATMENT DURATION; TUBERCULIN TEST; WORLD HEALTH ORGANIZATION; COMPARATIVE STUDY; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; EXPERT WITNESS; FEMALE; INTERNATIONAL COOPERATION; MALE; PATHOPHYSIOLOGY; PHYSIOLOGIC MONITORING; PRIMARY PREVENTION; STANDARDS;

ANTITUBERCULAR AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; EXPERT TESTIMONY; FEMALE; HUMANS; INTERNATIONALITY; LATENT TUBERCULOSIS; MALE; MONITORING, PHYSIOLOGIC; PRACTICE GUIDELINES AS TOPIC; PRIMARY PREVENTION;

EID: 84926434212     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00216814     Document Type: Letter

References (17)

1. Mack U, Migliori GB, Sester M, et al. LTBI: latent tuberculosis infection or lasting immune responses to M. tuberculosis? A TBNET consensus statement. Eur Respir J 2009; 33: 956-973.
2. Dye C, Scheele S, Dolin P, et al. Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. JAMA 1999; 282: 677-686.
3. Comstock GW, Livesay VT, et al. The prognosis of a positive tuberculin reaction in childhood and adolescence. Am J Epidemiol 1974; 99: 131-138.
4. Leung CC, Rieder HL, Lange C, et al. Treatment of latent infection with Mycobacterium tuberculosis: update 2010. Eur Respir J 2011; 37: 690-711.
5. Steele MA, Burk RF, DesPrez RM. Toxic hepatitis with isoniazid and rifampin. A meta-analysis. Chest 1991; 99: 465-471.
6. Nolan CM, Goldberg SV, Buskin SE. Hepatotoxicity associated with isoniazid preventive therapy: a 7-year survey from a public health tuberculosis clinic. JAMA 1999; 281: 1014-1018.
7. Grant AD, Mngadi KT, van Halsema CL, et al. Adverse events with isoniazid preventive therapy: experience from a large trial. AIDS 2010; 24: Suppl. 5, S29-S36.
8. Snider DEJr, Caras GJ. Isoniazid-associated hepatitis deaths: a review of available information. Am Rev Respir Dis 1992; 145: 494-497.
9. World Health Organization. Guidelines on the Management of Latent Tuberculosis Infection. Geneva, World Health Organization, 2014. Available from: www.who.int/tb/publications/ltbi-document-page/en/
10. Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009; 6: e1000097.
11. th Edition 2013. 2014. Ottawa, ON, Centre for Communicable Diseases and Infection Control, Public Health Agency of Canada, 2014. Available from: www.respiratoryguidelines.ca/tb-standards-2013
12. Centers for Disease Control and Prevention. Latent Tuberculosis Infection: A Guide for Primary Health Care Providers. Atlanta, GA, Centers for Disease Control and Prevention, 2013. Available from: www.cdc.gov/tb/publications/ltbi/pdf/TargetedLTBI.pdf
13. Saukkonen JJ, Cohn DL, Jasmer RM, et al. An official ATS statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med 2006; 174: 935-952.
14. Haut Conseil de la Santé Publique. Enquête Autour d'un Cas de Tuberculose: Recommandations Pratiques. [SurveyAround a Case of Tuberculosis Practical Recommendations]. Paris, Haut Conseil de la santé publique, 2013. Available from: www.hcsp.fr/Explore.cgi/Telecharger?NomFichier=hcspr20131025-enquetecastuberculoserecoprat.pdf
15. Sociedade Portuguesa de Pneumologia. Tratamento da Tuberculose Latente. Revisão Das Normas [Treatment of Latent Tuberculosis. Review of Rules]. Lisbon, Sociedade Portuguesa de Pneumologia, 2006. Available from: www. dgs.pt/documentos-e-publicacoes/tratamento-da-tuberculose-latente.aspx
16. Socialsyrelson. Rekommendationer för preventiva insatser mot tuberkulos - hälsokontroll, smittspårning och vaccination [Recommendations for preventive measures against tuberculosis - health surveillance, contact tracing and vaccination]. www.socialstyrelsen.se/smittskydd/sjukdomar/smittsammasjukdomarochsmittamnen/tuberkulos Date last accessed: November 11, 2014. Date Last updated: March 01, 2012.
17. Health Protection Surveillance Centre. Guidelines on the Prevention and Control of Tuberculosis in Ireland 2010. Dublin, Health Protection Surveillance Centre, 2010. Available from: www.hpsc.ie/AboutHPSC/ScientificCommittees/Publications/File,4349,en.pdf